CA3194483A1 - Novel cxcr4-targeting compounds - Google Patents

Novel cxcr4-targeting compounds

Info

Publication number
CA3194483A1
CA3194483A1 CA3194483A CA3194483A CA3194483A1 CA 3194483 A1 CA3194483 A1 CA 3194483A1 CA 3194483 A CA3194483 A CA 3194483A CA 3194483 A CA3194483 A CA 3194483A CA 3194483 A1 CA3194483 A1 CA 3194483A1
Authority
CA
Canada
Prior art keywords
residue
forms
lys
ipr
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194483A
Other languages
English (en)
French (fr)
Inventor
Francois Benard
Kuo-Shyan LIN
Zhengxing Zhang
Daniel KWON
David Perrin
Mihajlo Todorovic
Jerome LOZADA
Lee Lee LI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Provincial Health Services Authority
Original Assignee
University of British Columbia
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia, Provincial Health Services Authority filed Critical University of British Columbia
Publication of CA3194483A1 publication Critical patent/CA3194483A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3194483A 2020-10-21 2021-10-21 Novel cxcr4-targeting compounds Pending CA3194483A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063094839P 2020-10-21 2020-10-21
US63/094,839 2020-10-21
PCT/CA2021/051486 WO2022082312A1 (en) 2020-10-21 2021-10-21 Novel cxcr4-targeting compounds

Publications (1)

Publication Number Publication Date
CA3194483A1 true CA3194483A1 (en) 2022-04-28

Family

ID=81291055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194483A Pending CA3194483A1 (en) 2020-10-21 2021-10-21 Novel cxcr4-targeting compounds

Country Status (9)

Country Link
US (1) US20240100203A1 (https=)
EP (1) EP4232459A4 (https=)
JP (1) JP2023549469A (https=)
KR (1) KR20230092906A (https=)
CN (1) CN116457028A (https=)
AU (1) AU2021366975A1 (https=)
CA (1) CA3194483A1 (https=)
IL (1) IL301342A (https=)
WO (1) WO2022082312A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4511384A1 (en) * 2022-04-20 2025-02-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
US12614326B2 (en) * 2023-05-03 2026-04-28 GE Precision Healthcare LLC Methods and systems for scatter and tailing correction
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025171492A1 (en) * 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006035705A1 (de) * 2006-08-01 2008-02-07 Robert Bosch Gmbh Kolben einer Fahrzeugbremsanlagen-Kolbenpumpe
EP2377579A1 (en) * 2007-05-30 2011-10-19 Eli Lilly and Company Cyclic peptide CXCR4 antagonists
CN113150068B (zh) * 2017-09-20 2023-04-04 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy

Also Published As

Publication number Publication date
US20240342321A1 (en) 2024-10-17
US20240100203A1 (en) 2024-03-28
EP4232459A4 (en) 2024-12-04
KR20230092906A (ko) 2023-06-26
JP2023549469A (ja) 2023-11-27
CN116457028A (zh) 2023-07-18
EP4232459A1 (en) 2023-08-30
WO2022082312A1 (en) 2022-04-28
AU2021366975A1 (en) 2023-04-13
IL301342A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
CA3194483A1 (en) Novel cxcr4-targeting compounds
AU2019273132B2 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
JP7502801B2 (ja) ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージングおよびｇｒｐｒ関連障害の治療のための放射性標識ボンベシン由来化合物
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
US20250242064A1 (en) Cxcr4-targeting compounds, and methods of making and using the same
CA3201655A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
US12616761B2 (en) CXCR4-targeting compounds
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
WO2026055788A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241008

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241008

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251013

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251013

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251020

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251020

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251219

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122